Skip to main content
OnTheRiceSEE THE WORLD EARLY.
Search the world…
OnTheRice’s Emerging DataInvestment

ChemoMetec's earnings upgrade puts the cost bridge in focus

By OnTheRice · Sources and limitations · Report a correction

BULLISHHorizon24H
Probability Not recorded

ChemoMetec raised annual revenue and EBITDA guidance after stronger instrument demand and a lower cost base. Its EBITDA midpoint rose twice as much in kroner as its revenue midpoint. OTR's inference: the earnings case depends on costs and sales together. The 5 November update should help show how much comes from lasting improvements and how much from replacement timing.

Current priceNot available
24-hour changeNot available

Source confidenceNot assessed

Published
Check time

What’s changing?

OTR midpoint arithmetic: revenue midpoint rises DKK15m while EBITDA rises DKK30m, implying DKK15m lower revenue-minus-EBITDA cost base. This is derived arithmetic, not a company cost forecast. Earlier instrument sales rose 13% while consumables fell 4%, so replacement demand is not proof of recurring-use recovery.

Key points

  • For FY2026/27, company revenue guidance is DKK 560-590 million, previously DKK 545-575 million; EBITDA guidance is DKK 330-345 million, previously DKK 300-315 million. The company names NC-203 demand and a lower-than-expected cost base. The September annual release reported instrument sales up 13% and consumables down 4% in FY2025/26, while describing replacement of NC-200 with NC-203. OTR calculation from guidance midpoints: revenue midpoint rises DKK15m (DKK560m to DKK575m; +2.68%) and EBITDA midpoint rises DKK30m (DKK307.5m to DKK337.5m; +9.76%). Implied revenue-minus-EBITDA falls from DKK252.5m to DKK237.5m. This is midpoint arithmetic, not a company cost forecast.

What could change this view?

  • Replacing older instruments can bring sales forward. Lower costs may be temporary. The guidance upgrade does not establish a fair stock price or recovery in recurring consumables.

Bottom line

More likely direction: BULLISH over the next 24 hours.

This is based on the information recorded with this signal.

How likely is this call? · Three frameworks

ChemoMetec A/S (CHEMM) · BULLISH

Probability not recorded at publication. This earlier call is preserved without adding a hindsight estimate.

Read the shared method · Read the public probability method

Evidence behind this view

Checks whether separate pieces of evidence support the same view.

Recorded connection

OTR midpoint arithmetic: revenue midpoint rises DKK15m while EBITDA rises DKK30m, implying DKK15m lower revenue-minus-EBITDA cost base. This is derived arithmetic, not a company cost forecast. Earlier instrument sales rose 13% while consumables fell 4%, so replacement demand is not proof of recurring-use recovery.

We have not established a separate count of independent evidence clusters for this card. Several reports may rely on the same event or data provider.

What past price moves show

Compares today’s price moves with recorded past patterns.

No asset-specific historical pattern test is recorded separately for this card.

Evidence against this view

Shows evidence and risks that could challenge this view.

Recorded opposing evidence and risks

Replacing older instruments can bring sales forward. Lower costs may be temporary. The guidance upgrade does not establish a fair stock price or recovery in recurring consumables.

Why the direction changed

Explains recorded changes from expecting a rise to expecting a fall, or the reverse.

No documented bullish-to-bearish or bearish-to-bullish change is available for this card. We keep the original call and its time unchanged.

What people say vs the facts

Compares recorded public discussion with checked market facts.

No separate Reddit or public-discussion comparison with verified market data is recorded for this card. We cannot treat social attention as proof of a market move.

How past forecasts performed

Shows recorded forecast results and what they can teach us.

Recorded outcomes for this signal: 0 HIT, 1 MISS, 0 other or pending. These counts are not a forecast probability.

No tested mapping from evidence combinations to future success is recorded for this card. Confidence in sources and past outcomes do not establish a calibrated probability.

MISSHistorical record
Sources, original wording and price checks

Published

First published through Sites 06 Oct 2026, 12:18:23 SGT

24-hour check

  • ChemoMetec A/S (CHEMM)BULLISH ✕ MISS
    Price 1: 594.5 DKK
    At publication: 06 Oct 2026, 12:18:23 SGT
    Price 2 (+24h): 580 DKK
    At +24h: 07 Oct 2026, 12:18:23 SGT
    Change: -2.439%
    Price 1 source: 06 Oct 2026, 15:01:00 SGT (offset 9756.306925 s)
    Price 2 source: 06 Oct 2026, 22:59:00 SGT (offset -47963.693075 s)    First published through Sites: 06 Oct 2026, 12:18:23 SGT
    Call and evidence

    BULLISH / WATCH (ChemoMetec A/S, CHEMM, Nasdaq Copenhagen), conditional on both demand and cost benefits persisting through 5 Nov Q1 and FY2026/27.

    The price fell between the nearest observations to publication and +24 hours; the bullish direction was incorrect.

    Price series: CHEMM.CO · Copenhagen. Nearest available one-minute candle opening price to each fixed endpoint. Offsets are disclosed; original call and deadline are unchanged.

    Price 1 · at publication

    Exact endpoint: 06 Oct 2026, 12:18:23 SGT

    594.5 DKK · Nearest intraday candle (approximation)

    Source quote: 594.5 DKK · 06 Oct 2026, 15:01:00 SGT

    Source observation ↗

    Offset from required time: 9756.306925 seconds. Negative means before; positive means after.

    One-minute candle start; candle opening price. This is an approximation to the requested instant.

    Price 2 · exactly +24 hours

    Exact endpoint: 07 Oct 2026, 12:18:23 SGT

    580 DKK · Nearest intraday candle (approximation)

    Source quote: 580 DKK · 06 Oct 2026, 22:59:00 SGT

    Source observation ↗

    Offset from required time: -47963.693075 seconds. Negative means before; positive means after.

    One-minute candle start; candle opening price. This is an approximation to the requested instant.

    Change: -14.5 DKK (-2.439%). The price fell between the nearest observations to publication and +24 hours; the bullish direction was incorrect.

    Correction: Owner-requested full recalculation using nearest available intraday prices and disclosed offsets; includes previously settled calls. The previous result remains in the immutable assessment history.

What changed

Recorded public history

ChemoMetec raised annual revenue and EBITDA guidance after stronger instrument demand and a lower cost base. Its EBITDA midpoint rose…

This is the first recorded public view. Further public updates will appear here.

  1. ChemoMetec's earnings upgrade puts the cost bridge in focus

    ChemoMetec raised annual revenue and EBITDA guidance after stronger instrument demand and a lower cost base. Its EBITDA midpoint rose twice as much in kroner as its revenue midpoint. OTR's inference: the earnings case depends on costs and sales together. The 5 November update should help show how much comes from lasting improvements and how much from replacement timing.

    First published by OTR: 6 Oct, 12:18 SGTPublished by OTR: 6 Oct 2026, 12:18 SGT
    Upgrade of revenue and operating profit guidance ↗Positioning ChemoMetec for future growth ↗

Why the view changed

This is the first recorded view. Future source-backed updates will appear here.

Evidence, memory & review 2 linked sources

Named assets or actors: ChemoMetec A/S (CHEMM)

Directional takeaway: BULLISH / WATCH (ChemoMetec A/S, CHEMM, Nasdaq Copenhagen), conditional on both demand and cost benefits persisting through 5 Nov Q1 and FY2026/27.

OTR reasoning: OTR midpoint arithmetic: revenue midpoint rises DKK15m while EBITDA rises DKK30m, implying DKK15m lower revenue-minus-EBITDA cost base. This is derived arithmetic, not a company cost forecast. Earlier instrument sales rose 13% while consumables fell 4%, so replacement demand is not proof of recurring-use recovery.

Counterpoint: Replacing older instruments can bring sales forward. Lower costs may be temporary. The guidance upgrade does not establish a fair stock price or recovery in recurring consumables.

Source-grounded facts (paraphrased)

  • Time not supplied: For FY2026/27, company revenue guidance is DKK 560-590 million, previously DKK 545-575 million; EBITDA guidance is DKK 330-345 million, previously DKK 300-315 million. The company names NC-203 demand and a lower-than-expected cost base. The September annual release reported instrument sales up 13% and consumables down 4% in FY2025/26, while describing replacement of NC-200 with NC-203. OTR calculation from guidance midpoints: revenue midpoint rises DKK15m (DKK560m to DKK575m; +2.68%) and EBITDA midpoint rises DKK30m (DKK307.5m to DKK337.5m; +9.76%). Implied revenue-minus-EBITDA falls from DKK252.5m to DKK237.5m. This is midpoint arithmetic, not a company cost forecast. Source records: source-1, source-2

Source trail

Review status: PASS WITH ATTRIBUTION AND COUNTERCASE

No score or probability is presented.